Display options
Cite
Qu K, Gu J, Ye Y, et al. High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis. Oncoimmunology. 2017;6(2):e1265719doi: 10.1080/2162402X.2016.1265719.
Qu, K., Gu, J., Ye, Y., Williams, S. B., Dinney, C. P., Wu, X., & Kamat, A. (2017). High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis. Oncoimmunology, 6(2), e1265719. https://doi.org/10.1080/2162402X.2016.1265719
Qu, Kai, et al. "High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis." Oncoimmunology vol. 6,2 (2017): e1265719. doi: https://doi.org/10.1080/2162402X.2016.1265719
Qu K, Gu J, Ye Y, Williams SB, Dinney CP, Wu X, Kamat A. High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis. Oncoimmunology. 2017 Jan 03;6(2):e1265719. doi: 10.1080/2162402X.2016.1265719. eCollection 2017. PMID: 28344874; PMCID: PMC5353920.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2017 Jan 03;6(2):e1265719. doi: 10.1080/2162402X.2016.1265719. eCollection 2017.

High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis.

Oncoimmunology

Kai Qu, Jian Gu, Yuanqing Ye, Stephen B Williams, Colin P Dinney, Xifeng Wu, Ashish Kamat

Affiliations

  1. Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China.
  2. Department of Epidemiology, The University of Texas MD Anderson Cancer Center , Houston, TX, USA.
  3. Department of Urology, The University of Texas MD Anderson Cancer Center , Houston, TX, USA.

PMID: 28344874 PMCID: PMC5353920 DOI: 10.1080/2162402X.2016.1265719

Abstract

Bacillus Calmette-Guerin (BCG) therapy for non-muscle invasive bladder cancer (NMIBC) can significantly reduce the risk of recurrence and progression. However, BCG therapy may fail in up to a half of treated patients and may also cause toxicities. Biomarkers to predict the effectiveness of BCG therapy are desired to pre-select patients for BCG therapy to maximize efficacy while avoid unnecessary toxicity. Twelve cytokines were measured in 100 blood and 112 urine samples using cytokine antibody array and correlated with recurrence-free survival in overall and BCG-treated NMIBC patients. Of the 12 cytokines, interleukin (IL) -2, IL-8, IL-10, tumor necrosis factor (TNF)-α, granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon (IFN)-γ were measurable in more than 30% of peripheral blood leukocyte (PBL) samples. Only IL-8 in PBL was found to be significantly associated with tumor recurrence, especially in those who receiving BCG therapy (hazard ratio [HR] = 4.24; 95% confidence interval [95%CI] = 1.65-10.88;

Keywords: Antibody array; BCG therapy; IL-8; bladder cancer; tumor recurrence

References

  1. Breast Cancer Res. 2013;15(4):210 - PubMed
  2. J Immunol. 1992 May 15;148(10):3216-20 - PubMed
  3. Expert Opin Ther Targets. 2012 May;16(5):491-7 - PubMed
  4. J Urol. 2002 Nov;168(5):2232-5 - PubMed
  5. Eur Urol. 2014 Jan;65(1):69-76 - PubMed
  6. J Urol. 1996 Feb;155(2):483-7 - PubMed
  7. Clin Biochem. 2004 Aug;37(8):673-8 - PubMed
  8. J Clin Invest. 1995 Feb;95(2):586-92 - PubMed
  9. Urology. 2003 Jul;62(1):162-6 - PubMed
  10. J Urol. 1997 Nov;158(5):1728-31; discussion 1731-2 - PubMed
  11. Clin Cancer Res. 2003 Aug 1;9(8):3167-75 - PubMed
  12. Clin Genitourin Cancer. 2009 Aug;7(2):E16-23 - PubMed
  13. Eur Urol. 2013 Oct;64(4):639-53 - PubMed
  14. Eur Urol. 2003 Oct;44(4):429-34 - PubMed
  15. BMC Urol. 2012 May 04;12:12 - PubMed
  16. J Immunol Methods. 2003 Apr 1;275(1-2):251-5 - PubMed
  17. Eur Urol. 2012 Jan;61(1):128-45 - PubMed
  18. Oncotarget. 2015 Sep 22;6(28):26065-78 - PubMed
  19. Tumour Biol. 1998;19(6):470-6 - PubMed
  20. J Urol. 2007 Jan;177(1):353-8 - PubMed
  21. Eur Urol. 2011 Jun;59(6):997-1008 - PubMed
  22. Clin Exp Immunol. 2014 Jul;177(1):261-8 - PubMed
  23. Immunology. 2011 Nov;134(3):235-45 - PubMed
  24. J Clin Oncol. 1996 Jun;14(6):1778-86 - PubMed
  25. Adv Clin Exp Med. 2014 Nov-Dec;23(6):877-84 - PubMed
  26. Future Oncol. 2014 Jun;10(8):1443-56 - PubMed
  27. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29 - PubMed
  28. Urol Res. 1997;25(1):31-4 - PubMed
  29. J Urol. 2000 Dec;164(6):2129-33 - PubMed
  30. J Immunol. 1993 Sep 1;151(5):2725-32 - PubMed
  31. BMC Urol. 2012 Jun 13;12:18 - PubMed
  32. J Urol. 2003 Sep;170(3):964-9 - PubMed
  33. Eur Urol. 2016 Feb;69(2):197-200 - PubMed
  34. J Urol. 1997 Oct;158(4):1340-4 - PubMed
  35. Front Biosci. 2005 Jan 01;10:853-65 - PubMed
  36. Eur J Immunol. 2011 Jan;41(1):246-51 - PubMed
  37. Expert Rev Proteomics. 2007 Apr;4(2):299-308 - PubMed

Publication Types

Grant support